The following full text is a publisher's version.

For additional information about this publication click this link. http://hdl.handle.net/2066/70382

Please be advised that this information was generated on 2020-02-13 and may be subject to change.
Ethical Aspects of Tissue Engineering: A Review

Rob B.M. de Vries, M.A., M.Sc.,† Anke Oerlemans, M.A., M.Sc.,† Leen Trommelmans, M.A., M.Sc.,‡ Kris Dierickx, Ph.D.,‡ and Bert Gordijn, Ph.D.†

Tissue engineering (TE) is a promising new field of medical technology. However, like other new technologies, it is not free of ethical challenges. Identifying these ethical questions at an early stage is not only part of science’s responsibility toward society, but also in the interest of the field itself. In this review, we map which ethical issues related to TE have already been documented in the scientific literature. The issues that turn out to dominate the debate are the use of human embryonic stem cells and therapeutic cloning. Nevertheless, a variety of other ethical aspects are mentioned, which relate to different phases in the development of the field. In addition, we discuss a number of ethical issues that have not yet been raised in the literature.

Introduction

Tissue engineering* (TE) is a promising new field of medical technology. If further developed, it might diminish suffering caused by tissue or organ damage and thereby lead to longer and healthier lives.1 However, like other new technologies, TE is not free of ethical challenges. Identifying these ethical questions at an early stage is not only part of science’s responsibility toward society, but also in the interest of the field itself: it enables the field to flourish by preventing it from investing time and money in directions that are likely to lack societal support.

Despite high hopes, TE is still in its infancy. There are as yet only a few clinical applications, mainly for skin, cartilage, and bone.2,3 However, even though the field is still largely focused on research, it is moving ever more closely to clinical practice. The number of clinical trials is steadily rising. Now, therefore, seems a suitable moment to reflect on the moral implications of this technology: the field has developed far enough to have a sufficiently clear view of the directions in which it is heading and has not yet developed too far, so that there is still opportunity to steer clear of undesirable directions and effects.

TE has not figured prominently in public debates, with the notable exception of research involving the use of human embryonic stem cells (hESCs). In this review, we map which ethical questions related to TE have already been documented in the scientific literature. Further, we discuss which other issues might be raised and which issues require closer attention.

Methods

To find articles that explicitly pay attention to ethical issues raised by or directly related to TE,† the databases PubMed, EMBASE, and Web of Science were searched using the following combinations of terms: “tissue engineering” & ethic*, “tissue engineered” & ethic*, “regenerative medicine” & ethic*, “tissue engineering” & moral, “tissue engineered” & moral, and “regenerative medicine” & moral. The search was limited by date (published before 01-01-2008) and language (English). Papers in which ethic* referred to the product name Ethicon were excluded, as well as papers that contained one of the above-mentioned combinations of search terms, but in which the ethical issues discussed did not pertain to tissue engineering/regenerative medicine. Further, the most important journals in the field of tissue engineering and regenerative medicine—Tissue Engineering, Biomaterials, Journal of Tissue Engineering and Regenerative Medicine, Regenerative Medicine, and the Journal of Regenerative Medicine—were searched using the keywords ethic* and moral. These searches combined yielded 203

*We use “tissue engineering” (TE) in the sense of ex vivo TE. An ex vivo tissue-engineering product typically consists of three elements: cells (human, either autologous or allogeneic, or xenogeneic), a supporting structure (e.g., an extracellular matrix or scaffold), and biomolecules (e.g., growth factors). Moreover, these elements are combined in vitro before the construct is implanted in the body.

†Authors may have a different or broader conception of TE than we do, but we take their remarks about the ethical aspects of TE into account insofar as they apply to TE in the restricted sense in which we use the term.

1Section Ethics, Philosophy, and History of Medicine, Scientific Institute for Quality of Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
2Faculty of Medicine, Centre for Biomedical Ethics and Law, Catholic University of Leuven, Leuven, Belgium.
papers. These papers were studied and classified according to the ethical aspects of TE mentioned and to the type of journal in which they appeared.

Results

Papers classified according to issue

Table 1 shows the 10 ethical issues related to TE that are most frequently mentioned or discussed in the scientific literature. The ethical question that dominates is the use of hESCs. About 70% of the selected articles refer to the moral problems raised by these cells. These articles range from ethical or ethically oriented papers extensively discussing issues like the moral status of human embryos (e.g., Refs.4–18) via scientific reviews that describe the moral opposition evoked by hESCs as one of the disadvantages of using these cells (e.g., Refs.19–44) to research papers that present alternative sources of stem cells—for example, stem cells derived from adult bone marrow,5–49 amniotic fluid,50–52 placenta,53,54 or umbilical cord (blood)55–58 or acquired through reprogramming of differentiated cells,59–66—or ways to acquire hESCs without destroying (viable) embryos.67–72

A closely related topic that is also often discussed or mentioned is therapeutic or research cloning. About 20% of the selected articles refer to the moral problems involved in therapeutic cloning. Some articles merely mention that cloning is considered by many to be morally problematic (e.g., Refs.8,15,37,40,42,63,65,68,69,73–75); other papers elaborate on the ethical objections to this technique. The objections most often discussed are the objection that the creation of a human embryo specifically for research purposes and its subsequent destruction contravene its moral status,4,6,9,17,20,43,76,77 the objection that permitting therapeutic cloning will inevitably put us on a slippery slope toward reproductive cloning,4,9,17,20,29,43,76,77 and ethical questions related to paid egg donation. These latter questions include (1) the risks involved in hyperstimulation of the ovaries and the surgical or transvaginal recovery of oocytes for women who will not directly profit from the donation and (2) the commodification of both oocytes and women.8,17,20,29,43,76,77

But the use of hESCs and therapeutic cloning are not the only ethical issues mentioned in the literature. A variety of other questions are discussed, which relate to different phases in the development of the field of TE.

Papers classified according to phase in development

Classified according to the phase in the development of the field of TE to which they seem most relevant, the following ethical issues beyond the use of hESCs and therapeutic cloning are mentioned or discussed.

Fundamental and preclinical research. Four clusters of ethical issues associated with this early phase in the development of TE can be distinguished: issues related to (1) the source of cells (to be) used in TE products, (2) the donation of cells, (3) the use of (laboratory) animals, and (4) morally problematic “techniques.”

(1) Embryonic stem cells are not the only cells that are considered morally problematic because of their origin. First, several arguments are brought forward against the use of fetal cells,6 in particular embryonic germ cells: the primary source of these cells is induced abortion, which is in itself a morally controversial intervention;37,50,73 some argue that using fetal tissue from elective abortion is a way of legitimizing abortion and this will encourage institutions to increase the number of abortions;6,73 some fear that women might conceive specifically to obtain fetal cells via abortion.6

Also controversial is the use of xenogeneic cells or materials for TE purposes. The main arguments mentioned are the risk of introducing pathogenic agents (bacteria, viruses, or other infectious agents) into humans,24,83–94 the serious immunological problems xenogeneic cells may cause if they are not genetically altered or physically isolated,24,83,90 and the risk of disease transmission24,83,87,88,91 and the public acceptability of using animal cells/tissue,87,88,91 Some people object to the introduction of animal cells/tissue into the human body as such; others reject the use of material from specific animal species on the basis of religious precepts (e.g., reservations of Muslims and Jews regarding the use of porcine cells/tissue).85

Finally, even though the use of allogeneic cells is generally considered to be less problematic than the use of xenogeneic cells, the immunological problems involved in the use of these cells24,90,91,95 and the risk of disease transmission24,90,95 are sometimes mentioned as reasons against the use of this type of cell.

(2) A second cluster of moral issues pertains to the donation/collection of cells for TE. The requirement of obtaining informed consent is often stressed: donors should be informed as fully as possible about future uses of their tissue/cells, and no tissue/cells may be used without the consent of the donor.4,16,81,96–103 Similarly, the importance of protecting the privacy of the donor is pointed out, for example through the anonymization of samples used in scientific research.16,96–98,101–105 Further, many au-
that it would violate human dignity and that it could lead to
most often mentioned against granting property rights are
cine.84,86,90,98,102,103,105,106
but also of these cells themselves.13,16,90,102,107–109 The reasons
patenting not only of processes involving human (stem) cells,
a necessary condition for allowing paid donation and the
subject to property rights. Acknowledging these rights seems
often as a question of whether the human body can be

A closely related issue is the question of the ownership of
the human body and its parts. 13,76,81,95,99–102,104,106 This
question is sometimes interpreted as a question of who has
authority over the use of collected cells/tissue,99,101 but more
often as a question of whether the human body can be
subject to property rights. Acknowledging these rights seems
a necessary condition for allowing paid donation and the
patenting not only of processes involving human (stem) cells,
but also of these cells themselves. 13,16,90,102,107–109 The reasons
most often mentioned against granting property rights are
that it would violate human dignity and that it could lead to
exploitation of poor people.13,81,95,106

Moreover, there is considerable debate about the most
desirable mode of banking of umbilical cord
blood.14,99,104,110–114 Stem cells from this blood might in the
future be used for regenerative purposes. Several ethical
arguments are advanced for preferring public banks to private,
commercial banks that collect cord blood for autologous use.
A number of authors stress that at present it is doubtful
whether cord blood stem cells will ever be used for autolo-
gous transplantation. To claim that cord blood banking is
a way to save the key components for future medical
treatment of your child is therefore to create false
hope.99,104,110–112 This is especially problematic because the
promotional materials of these commercial banks are tar-
geted at prospective parents at a vulnerable time.104,110–112
Moreover, private banks may take cord blood out of circu-
tation that might have been collected by public banks for
allogeneic transplantation in unrelated recipients. Donating
to private banks therefore conflicts with the principle of
solidarity.99,104,112

(3) A small number of papers pay attention to the moral
justifiability of using animals either as a source of cells or for
TE research.88,115,116 Laboratory animals are used to study
the fundamental processes involved in TE, and they function
as models of human disease for testing new products. As
several authors115,116 stress, these animals can experience
substantial discomfort, and experiments should therefore
only be performed when no alternatives are available and
when the benefit of the experiment outweighs the animals’
suffering. On the other hand, several other papers point to
the prospects of using human cell cultures and TE products
like artificial skin as alternatives for laboratory animals in
safety testing or drug discovery.97,117–119

(4) Besides objections to therapeutic cloning, moral reser-
vations regarding certain other “techniques” are mentioned,
notably regarding the genetic engineering of cells for TE
products85,90,120,121 the mixing of human and animal cells
or genetic material (e.g., the use of interspecies nuclear
transfer or the engrafting of human ES cells into a mouse
blastocyst).24,83,122,123

Clinical trials. Although an integral analysis of the ethical
aspects of clinical trials with TE products is lacking, a
number of issues are discussed. Most important among these
are the requirement of informed consent of the partici-
pant,16,124,125 the importance of and difficulties involved in
risk–benefit analysis,16,91,124 the need for clear criteria of ef-
ficacy and safety,38,86,91,126,127 and the desirability of long-
term posttrial follow-up including the establishment of a
registry.126

Clinical practice (short-term). The following issues men-
tioned in the literature seem to be particularly relevant when
TE products are introduced in clinical practice: the informed
consent of patients, especially if the product contains xeno-
geneic material;85,88,93,102 in view of public health, the
necessity of complying with the regulations of Good
Manufacturing & Laboratory Practice;98,105 and justice in
the distribution of treatments with TE products, both
among different groups within Western societies and be-
tween these societies and developing countries.84,124,128

Advanced clinical application (long-term). Besides the issues
previously described, a number of more philosophical
questions about TE are raised. The first question can be
concisely described by slightly adapting the title of one of the
papers about stem cells31—TE: immortality or a healthy old
age? In other words, should TE only or primarily be used to
fight the negative effects of ageing or may it also be deployed
in the extension of the human lifespan?15,18,31,90,128–132
Second, is it morally desirable to use TE to enhance human
capabilities?124,128,133 And how will TE affect our view of and
attitude toward our body?75,81,90,128,132

Distribution among phases. In conclusion, and taking a more
quantitative perspective, the preclinical phase is dominant
not only in terms of the number of issues associated with it,
but also in terms of the number of articles that pay attention
to issues most relevant to this phase (Table 2). Even if papers
referring to the use of hESCs and therapeutic cloning are not
included, more papers pertain to the preclinical phase than
to all three later phases combined.

Papers classified according to type of journal
A large majority of the selected papers are published in
scientific/biomedical journals; only a small minority can be
found in journals in the domain of (medical) ethics, social
science, or the humanities (Table 3). Not all articles in the
biomedical journals are purely scientific; some are of a more
reflective nature. Nevertheless, by far most authors have a
scientific/biomedical affiliation.

Discussion
Even though the use of hESCs and the closely related topic
of therapeutic cloning dominate the scientific literature
dealing with the ethical aspects of TE, that does not mean

<table>
<thead>
<tr>
<th>Phase development TE</th>
<th>Number of papersa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preclinical research</td>
<td>55b</td>
</tr>
<tr>
<td>Clinical trials</td>
<td>8</td>
</tr>
<tr>
<td>Clinical practice</td>
<td>12</td>
</tr>
<tr>
<td>Advanced clinical application</td>
<td>14</td>
</tr>
</tbody>
</table>

aTotal number of selected papers: 203. Papers referring to more
than one issue are grouped under each of these issues. bPapers referring to hESCs and/or cloning are not included.
that these issues are at present most relevant from an ethical point of view. Current applications of TE are not yet using cells derived from hESCs, and it is unlikely that they will do so in the near future\(^\text{134}\) (although research in this direction is being carried out\(^\text{135–137}\)). Moreover, even if TE products based on hESCs will be developed, still many TE products will contain other types of (stem) cells. And although there are strong indications that it is in principle possible to acquire human blastocysts through somatic cell nuclear transfer,\(^\text{138}\) it is as yet far from evident that it will be possible to obtain in a safe and efficient way differentiated cells, let alone tissues or organs, derived from hESCs acquired via therapeutic cloning.\(^\text{20,139,140}\) In other words, the strong focus of the debate on the issues of hESCs and therapeutic cloning is not warranted.

Although, apart from hESCs and therapeutic cloning, a large number of ethical issues relevant to the development of TE are already being mentioned in the literature, we believe that there are significant issues that are not yet covered or did not get the attention they deserve (cf. Refs.\(^\text{141–143}\)). Some of these issues have been discussed in relation to other new medical technologies like cell and gene therapy, but we consider it important that they be explicitly discussed in the context of TE.

First, the need for obtaining informed consent from a cell donor is greatly stressed. However, the problems involved in meeting the ideals of informed consent are hardly discussed: Is it possible to provide all relevant information regarding future uses and tests? If not, will general information suffice? Will the donor be able to (fully) understand the detailed and scientific information given? If not, what is his/her consent worth?\(^\text{15}\)

Second, although the need for animal models that more closely resemble human diseases is noted,\(^\text{115,123,148–150}\) the significance of this fact for the justifiability of animal experiments is largely ignored. Further, since the TE products that are being developed as alternatives to laboratory animals are not primarily intended to replace experiments for TE research, it is still an open question whether the development of TE will lead to an overall reduction of the number of laboratory animals used.

Third, more attention needs to be paid to the ethical issues involved in clinical trials,\(^\text{15}\) in particular to the significance of the complexity of TE products for dealing with these issues.

<table>
<thead>
<tr>
<th>Type of journal</th>
<th>Number of papers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biomedical journal</td>
<td>190</td>
</tr>
<tr>
<td>Other (ethics, social science, and humanities)</td>
<td>13</td>
</tr>
</tbody>
</table>

Table 3. Papers Classified According to Type of Journal

TE products are complex in at least the following three respects: (1) TE products show a certain amount of variability because they contain metabolically active cells in the dynamic environment of the extracellular scaffolds; (2) implanting a TE product initiates an ongoing interaction between the product and the recipient’s body, which also varies to some extent; (3) implanting a TE product is an irreversible process—once the process of integration and regeneration is initiated, it is impossible to reverse it completely.\(^\text{143}\) This complexity seems to have consequences for the possibility of meeting the requirements of informed consent (cf. consent cell donation), of making an accurate risk–benefit analysis, for the generalizability of the results of trials and for the necessity of a long-term posttrial follow-up. Moreover, since TE is claimed to be part of a new medical paradigm, namely, that of regenerative medicine, it would seem that the goal of a trial testing the efficacy of a TE product should be to demonstrate not only that the treatment is as effective as current treatments, but also that there is in fact regeneration in the body.

Fourth, given that TE products will likely be rather expensive, broad access to these products will be dependent on reimbursement. However, the lack of standards for clinical trials and persisting uncertainty whether treatments with TE products will not only be safe but also more effective than current treatments decrease the likelihood that they will be refunded. But if reimbursement were not provided, application of these products would be the privilege of the happy few, and all the fruits of publicly funded research would be reaped by private hands.

Fifth, two groups of people are likely to benefit especially from TE: young people with congenital diseases, for whom TE might provide a long-term solution superior to any therapy currently available, and the elderly, who suffer more than average from degenerative diseases. In the light of the limited budgets for health care, who should profit most? Apart from the issue of just allocation—which group is most entitled to these treatments?—a number of other considerations seem to be relevant for answering this question.\(^\text{89}\) Thus, although application for elderly people could significantly increase their quality of life, this application also raises anthropological and socioeconomic questions. Would large-scale application to the problems of the elderly lead to a medicalization of ageing; that is, would ageing increasingly be regarded as a medical problem to be treated rather than as a natural physiological condition? And would application to the elderly aggravate the socioeconomic problems of an ageing society? Pediatric applications, on the other hand, raise their own set of problems, for example, regarding the long-term safety and efficacy as well as the validity of the substituted consent given by the parents.\(^\text{11}\)

---

\(^{**}\) For a similar discussion of the amount of information that is required or desirable for informed consent regarding the collection of tissue samples, see, for example, Refs.\(^\text{144,145}\)

\(^{11}\) For a general discussion of similar problems in the context of informed consent for clinical trials, see, for example, Refs.\(^\text{146,147}\)

\(^{15}\) For a general discussion of the ethical issues in clinical trials, see Ref.\(^\text{151}\)

\(^{88}\) Acknowledging that these considerations are of diverse ethical nature and deserve attention in their own right, we here focus on how they might bear on the question of who should profit most from TE products.

\(^{**}\) The issue of the status of the ageing process has been mainly discussed in the context of research into the extension of the maximum human lifespan, see, for example, Refs.\(^\text{152,153}\)

\(^{11}\) For a general discussion of the economics and ethics of anti-ageing interventions, see, for example, Ref.\(^\text{154}\)

\(^{12}\) For a general discussion of the ethical issues in neonatal surgery, see, for example, Ref.\(^\text{155}\)
Sixth, even though a few authors\textsuperscript{128,133} mention ethical issues involved in using TE for enhancing the human body, the examples they use (extending the range of our senses or improving cognitive function for healthy individuals through cell-based therapies) are unlikely to be realized in the near future. An application beyond therapy that will probably be available much sooner is the use of TE products for cosmetic purposes (e.g., more natural breast implants; cf. the near future. An application beyond therapy that will or improving cognitive function for healthy individuals the examples they use (extending the range of our senses issues involved in using TE for enhancing the human body,(Ref.\textsuperscript{156,157})). The question of the desirability of such non-medical applications of TE needs to be addressed.\textsuperscript{158}

Although all the above-mentioned issues are relevant for an ethical assessment of TE, they are not equally urgent. We would argue that special attention should presently be devoted to the ethical questions related to clinical trials, because of the stage of development of the field of TE—on the verge from preclinical research to clinical trials—and because of the relatively scarce attention paid to this phase so far. Moreover, the ethical issues involved in the collection of cells (informed consent, privacy/confidentiality, and altruistic vs. paid donation) should remain a focus of reflection, for without an ethically satisfactory regulation of cell donation even preclinical research would should come to a halt.

The fact that so many papers in scientific/biomedical journals pay attention to potential ethical issues related to TE clearly indicates that tissue engineers already reflect on the ethical aspects of their work. The involvement of professional ethicists, on the other hand, still seems relatively low. We would argue that, to ensure an adequate identification and analysis of the ethical aspects of TE, ethicists should become more engaged in the ethical debate on TE. However, to prevent the ethical reflections from becoming too abstract or irrelevant in the light of scientific developments, close collaboration with scientists in the field of TE is of vital importance. Combining the intellectual capacities of scientists and ethicists should lead to ethical considerations that have both reflective depth and practical relevance.

Acknowledgments

The research for this contribution was supported by the Dutch Program Tissue Engineering (R.d.V. and B.G.), the EuroSTEC-project, funded by the European Commission, FP6 (A.O.), and the STEPS-project, funded by the European Commission, FP6-500465 (L.T. and K.D.).

References

7. Denker, H. Embryonic stem cells: an exciting field for basic research and tissue engineering, but also an ethical dilemma? Cells Tissues Organs \textbf{165}, 246, 1999.
12. Hug, K. Therapeutic perspectives of human embryonic stem cell research versus the moral status of a human embryo—does one have to be compromised for the other? Medicina (Kaunas) \textbf{42}, 107, 2006.
43. Weissman, I. Stem cell research: paths to cancer therapies and regenerative medicine. JAMA 294, 1359, 2005.
85. Enoch, S., Shaaban, H., and Dunn, K.W. Informed consent should be obtained from patients to use products (skin substitutes) and dressings containing biological material. J Med Ethics 31, 2, 2005.
117. de Bruggerolle, A. SkinEthic Laboratories, a company devoted to develop and produce in vitro alternative methods to animal use. ALTEX 24, 167, 2007.
152. Partridge, B., and Hall, W. The search for Methuselah: should we endeavour to increase the maximum human lifespan? EMBO Rep 8, 888, 2007.